Skip to main content

Table 1 First line trials of 1 st generation TKI in EGFR mutated patients

From: Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

Study N OR% mPFS (mo) mOS (mo)
First Signal 4     
Gefitinib 26 85 8 27.2
Cis/Gem 16 38 2.1 25.6
IPASS 5     
Gefitinib 132 71 9.5 19
Carbo/Taxol 129 47 6.5 18
WJTOG 6     
Gefitinib 86 62 9.2 30.9
Cis/Doce 86 31 6.3 NR
NEJOG 7     
Gefitinib 114 74 10.8 27.7
Carbo/Taxol 110 31 5.4 26.6
OPTIMAL 8     
Erlotinib 83 83 13.1 NR
Carbo/Gem 72 36 4.6 NR
EURTAC 9     
Erlotinib 86 58 9.7 NR
Plat Doublet 87 15 5.2 NR
  1. N, number of patients; OR, objective response rate; mPFS, median progression free servival; mOS, median overall survival; mo, months; cis, cisplatin; gem, gemcitabine; carbo, carboplatin; doce, docetaxel; plat, platinum; NR, not reached.